Movement disorders News and Research RSS Feed - Movement disorders News and Research

Education can help people better understand individuals with facial paralysis

Education can help people better understand individuals with facial paralysis

A little bit of sensitivity training can help people form better first impressions of those with facial paralysis, reducing prejudices against people with a visible but often unrecognizable disability, new research from Oregon State University indicates. [More]
Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. [More]
FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States. [More]
Disturbed gut microbiome linked to Parkinson’s disease

Disturbed gut microbiome linked to Parkinson’s disease

Research suggests that the intestinal microbiome may be altered in patients with Parkinson’s disease, with some alterations being specific to the motor subtype. [More]
Nonmotor symptoms cluster in Parkinson’s disease patients

Nonmotor symptoms cluster in Parkinson’s disease patients

Nonmotor symptoms tend to appear in specific clusters in patients with Parkinson’s disease and often predate the onset of motor symptoms, research shows. [More]
FDA receives Actavis' NDA resubmission for cariprazine

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors. [More]
Loyola neurologist finds little scientific evidence that brain games improve cognitive function

Loyola neurologist finds little scientific evidence that brain games improve cognitive function

Computerized brain games that are advertised as a way to help boost intelligence and prevent dementia will be popular Christmas gifts this year. [More]
Patients with Parkinson's disease have different microbiota in their intestines

Patients with Parkinson's disease have different microbiota in their intestines

Parkinson's disease sufferers have a different microbiota in their intestines than their healthy counterparts, according to a study conducted at the University of Helsinki and the Helsinki University Central Hospital. Researchers are now trying to determine what the connection between intestinal microbes and Parkinson's disease is. [More]
Clinical markers help identify PD patients with cholinergic deficits

Clinical markers help identify PD patients with cholinergic deficits

Assessing patients for clinical markers of cholinergic system denervation is viable and can help identify suitable individuals for trials of new anticholinergic drugs, researchers believe. [More]
Simple tests can help differentiate between early-stage PD and atypical parkinsonism

Simple tests can help differentiate between early-stage PD and atypical parkinsonism

Two simple tests conducted during the neurological exam can help clinicians differentiate between early-stage Parkinson's disease (PD) and atypical parkinsonism. By asking patients to perform a tandem gait test and inquiring whether they are still able to ride a bicycle, clinicians can ascertain whether medio-lateral balance is impaired, a defining characteristic of atypical parkinsonism. [More]
Stopping the death of synapses: an interview with Dr Soledad Galli

Stopping the death of synapses: an interview with Dr Soledad Galli

Synapses are the sites that connect neurons – sites where information is passed from one neuron to another. They are highly specialized structures and synaptic function is crucial for normal brain function. [More]
Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. [More]
Levodopa dose linked to malnutrition risk in Parkinson’s disease

Levodopa dose linked to malnutrition risk in Parkinson’s disease

The malnutrition often seen in patients with Parkinson’s disease could be partly an effect of levodopa medication, research suggests. [More]
Parkinson's disease can migrate from gut to brain, shows research

Parkinson's disease can migrate from gut to brain, shows research

Parkinson's disease is strongly linked to the degeneration of the brain's movement center. In the last decade, the question of where the disease begins has led researchers to a different part of the human anatomy. [More]
Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery). [More]
U-M scientists launch $11.5 million effort to better understand cause of Parkinson's disease

U-M scientists launch $11.5 million effort to better understand cause of Parkinson's disease

Deep in the brains of the million Americans with Parkinson's disease, changes to their brain cells put them at high risk of dangerous falls -- a problem that resists even the most modern treatments. [More]
Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

A multidisciplinary team of experts affiliated with the Cedars-Sinai Movement Disorders Program will present a free conference for patients, families and caregivers on treatment options for dystonia, which causes painful and potentially crippling muscle contractions. [More]
Standard cognition test falls short in Parkinson’s disease patients

Standard cognition test falls short in Parkinson’s disease patients

There is a wide range of cognitive function, including dementia, among patients with Parkinson’s disease who are classed as cognitively normal on the Mini-Mental State Examination, research shows. [More]

Researchers gain new insight into how the body moves while walking

Researchers at The Ohio State University have gained new insight into how the body moves when we're walking. [More]
Research evidence supports use of deep brain stimulation for OCD patients

Research evidence supports use of deep brain stimulation for OCD patients

Available research evidence supports the use of deep brain stimulation (DBS) for patients with obsessive-compulsive disorder (OCD) who don't respond to other treatments, concludes a review in the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]